-transparent.png){kind=logo}
Ten patients (two with normal, eight with impaired renal function) on their usual diet were treated with cefodizime (HR 221) for seven days. The dosage was 4 g/day, adapted to renal function as appropriate. Platelet function, plasma coagulation and vitamin K metabolism were investigated before and on day 7 of therapy. Platelet function and plasma coagulation remained unchanged, regardless of the size of the serum antibiotic trough levels, in both normal and impaired renal function. Vitamin K1 metabolism remained unaffected, since no increase in vitamin K1 2,3 epoxide in the circulation was observed during the therapy. Cefodizime (HR 221), a parenteral aminothiazole cephalosporin, does not affect hemostasis.
K Andrassy, and
J Koderisch, and
D Trenk, and
E Jähnchen, and
A Iwand
November 1994,
Journal of clinical pharmacology,
K Andrassy, and
J Koderisch, and
D Trenk, and
E Jähnchen, and
A Iwand
May 1987,
Antimicrobial agents and chemotherapy,
K Andrassy, and
J Koderisch, and
D Trenk, and
E Jähnchen, and
A Iwand
August 1967,
Postgraduate medical journal,
K Andrassy, and
J Koderisch, and
D Trenk, and
E Jähnchen, and
A Iwand
June 1975,
Clinical pharmacology and therapeutics,
K Andrassy, and
J Koderisch, and
D Trenk, and
E Jähnchen, and
A Iwand
January 1982,
Acta medica Scandinavica. Supplementum,
K Andrassy, and
J Koderisch, and
D Trenk, and
E Jähnchen, and
A Iwand
January 1991,
Chemotherapy,
K Andrassy, and
J Koderisch, and
D Trenk, and
E Jähnchen, and
A Iwand
September 1977,
The Journal of antimicrobial chemotherapy,
K Andrassy, and
J Koderisch, and
D Trenk, and
E Jähnchen, and
A Iwand
April 2007,
Urological research,
K Andrassy, and
J Koderisch, and
D Trenk, and
E Jähnchen, and
A Iwand
April 1976,
British journal of anaesthesia,
K Andrassy, and
J Koderisch, and
D Trenk, and
E Jähnchen, and
A Iwand
January 1980,
British journal of clinical pharmacology,
